Physician profile
Kavitha Selvan
NPI 1437687001
$3,381.41
in general payments reported to CMS, 2019-2025
10 companies · $583 in 2025
The $583 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $77.52 · 2021: $238 · 2022: $764 · 2023: $985 · 2024: $734 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,302.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,683.28 | 2020-2025 | Fasenra, Tezspire |
| United Therapeutics Corporation | $573.04 | 2024-2025 | Tyvaso, Steen Solution, Remodulin |
| Glaxosmithkline, LLC. | $450.63 | 2022-2025 | Nucala, Trelegy Ellipta |
| Amgen INC. | $247.22 | 2023 | Tezspire |
| Conmed Corporation | $154.83 | 2024 | Conmed Biliary |
| Genzyme Corporation | $140.61 | 2022 | |
| Insmed, INC. | $50.55 | 2025 | Arikayce |
| Takeda Pharmaceuticals U.S.A., INC. | $35.42 | 2025 | Glassia |
| Inogen, INC. | $28.44 | 2025 | |
| Genentech USA, INC. | $17.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kavitha Selvan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.